Neuren Pharmaceuticals

Rising Rett Diagnoses Will Expand Orphan And Pediatric Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

21 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

AU$30.90

44.4% undervalued

21 Aug

AU$17.17

10.6%

5.0%

Author's Valuation

AU$30.9

44.4% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

AU$30.9

44.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-6.25%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.48%

Calculation

AU$148.46m

Earnings '28

31.66x

PE Ratio '28

AU$4.70b

Market Cap '28

AU$4.70b

Market Cap '28

127.01m

No. shares '28

AU$37.01

Share Price '28

AU$37.01 Share Price '28

Discounted to 2025 @ 6.48% p.a.

AU$30.65

Fair Value '25